Dowling & Yahnke’s Immunic IMUX Stock Holding History

Dowling & Yahnke’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50	Closed	-$136K	–	279
2018 Q1	$136K	Buy	+50	New	+$115K	0.01%	278
2017 Q4	–	Sell	-125	Closed	-$252K	–	294
2017 Q3	$252K	Buy	+125	New	+$163K	0.03%	255

Other funds holding IMUX

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dowling & Yahnke's IMUX Position: Q2 2018 in Review

Dowling & Yahnke sold out of Immunic (IMUX) in Q2 2018, closing a stake of 50 shares — an estimated $136K sold.

Dowling & Yahnke first reported a position in IMUX in Q3 2017 and held it in 2 quarters. The position peaked at $252K in Q3 2017. 62 funds tracked by Wall St. Rank hold IMUX as of Q2 2018.

Dowling & Yahnke reported no remaining Immunic position as of Q2 2018 after selling out during the quarter.
Dowling & Yahnke sold 50 Immunic shares in Q2 2018, an estimated $136K.
Dowling & Yahnke first reported a position in Immunic in Q3 2017 and held it in 2 quarters.
Dowling & Yahnke's Immunic position peaked at $252K in Q3 2017.
62 funds tracked by Wall St. Rank held Immunic as of Q2 2018.

Based on Dowling & Yahnke's 13F filing for Q2 2018, filed 30 Jul 2018.